scholarly journals A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

2020 ◽  
Vol 9 ◽  
Author(s):  
Qian Wu ◽  
Yiting Xiong ◽  
Shujuan Zhang ◽  
Xinling Chen ◽  
Fengming Yi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Randomized Controlled Trials ◽  
Concurrent Chemoradiotherapy ◽  
Meta Analysis ◽  
Small Cell ◽  
Controlled Trials ◽  
Small Cell Lung ◽  
Once Daily ◽  
Randomized Controlled

Pooled subgroup analysis of twelve randomized controlled trials of immunotherapy in non-small cell lung cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20639-e20639
Author(s):  
Fang Yang ◽  
Yucai Wang ◽  
Aaron Scott Mansfield ◽  
Alex A. Adjei ◽  
Konstantinos Leventakos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Small Cell ◽  
Controlled Trials ◽  
Wild Type ◽  
Small Cell Lung ◽  
Randomized Controlled ◽  
Ecog Ps

e20639 Background: Multiple randomized controlled trials (RCTs) have shown a robust benefit of immunotherapy with immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). We did a meta-analysis to examine the benefit of ICI in various subgroups. Methods: PubMed was searched up to Jan 15, 2019 for RCTs comparing overall survival (OS) between ICI and control (without ICI) arms. Pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated for each subgroup. Interaction tests were done to compare relative benefit between opposed subgroups of interest (eg. men vs women; reported as Pheterogeneity). All analyses were performed with a random effects model in Comprehensive Meta Analysis (v2). Results: Twelve phase 2/3 RCTs involving 7244 patients were included. A significant OS benefit of ICI was found in both squamous and non-squamous histology. Current/former smokers, EGFR wild-type, and KRAS mutant patients had a significant OS benefit from ICI, but never smokers, EGFR mutant, and KRAS wild-type patients did not. An OS benefit of ICI was found in patients with or without baseline brain metastasis, PD-L1 < 1% or ≥1%, men or women, age < 65 or ≥65, and ECOG PS 0 or ≥1. No significant difference of relative benefit from ICI over control was found in patients with different PD-L1 expression, sex, age, or ECOG PS (Table). Conclusions: OS benefit of ICI in NSCLC was associated with a smoking history, wild-type EGFR or KRAS mutation. However, the OS benefit of ICI was seen regardless of histology, PD-L1 expression, sex, age, and ECOG PS. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document